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Abstract
Development of cheap, high-throughput, and reliable gene synthesis methods will broadly 
stimulate progress in biology and biotechnology1. Currently, the reliance on column-synthesized 
oligonucleotides as a source of DNA limits further cost reductions in gene synthesis2. 
Oligonucleotides from DNA microchips can reduce costs by at least an order of magnitude3,4,5, 
yet efforts to scale their use have been largely unsuccessful due to the high error rates and 
complexity of the oligonucleotide mixtures. Here we use high-fidelity DNA microchips, selective 
oligonucleotide pool amplification, optimized gene assembly protocols, and enzymatic error 
correction to develop a highly parallel gene synthesis platform. We tested our platform by 
assembling 47 genes, including 42 challenging therapeutic antibody sequences, encoding a total of 
~35 kilo-basepairs of DNA. These assemblies were performed from a complex background 
containing 13,000 oligonucleotides encoding ~2.5 megabases of DNA, which is at least 50 times 
larger than previously published attempts.
The synthesis of DNA encoding regulatory elements, genes, pathways, and entire genomes 
provides powerful ways to both test biological hypotheses as well as harness biology for our 
use. For example, since the use of oligonucleotides in deciphering the genetic code6,7 to the 
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recent complete synthesis of a viable bacterial genome8, DNA synthesis has engendered 
tremendous progress in biology. Currently, almost all DNA synthesis currently relies on the 
use of phosphoramidite chemistry on controlled-pore glass (CPG) substrates. The synthesis 
of gene-sized fragments (500–5,000 basepairs) relies on assembling many CPG-
oligonucleotides together using a variety of techniques termed gene synthesis2. 
Technologies to assemble verified gene-sized fragments into much larger synthetic 
constructs are now fairly mature8,9,10,11,12.
The price of gene synthesis has reduced drastically over the last decade. However, the 
current commercial price of gene synthesis, ~$0.40–1.00/basepair (bp), has begun to 
approach the relatively stable cost of the CPG oligonucleotide precursors (~$0.10–0.20/bp)1. 
At these prices, the construction of large gene libraries and synthetic genomes is out of reach 
to most. To achieve further cost reductions, many ongoing efforts focus on reducing the cost 
of the oligonucleotide precursors. For example, microfluidic oligonucleotide synthesis can 
reduce reagent cost by an order of magnitude and has been used for proof-of-concept gene 
synthesis13.
Another promising route is to harness existing DNA microchips, which can produce up to a 
million different oligonucleotides on a single chip, as a source of DNA. Previous efforts 
have demonstrated the ability to synthesize genes from DNA microchips3,4,5,14. These 
approaches have thus far failed to scale for at least three reasons. First, the error rates of 
chip-based oligonucleotides from DNA microchips are higher than traditional column-
synthesized oligonucleotides. Second, the assembly of gene fragments becomes increasingly 
difficult as the diversity of the oligonucleotide mixture becomes larger. Finally, the potential 
for cross-hybridization between individual assemblies imposes strong constraints on the 
sequences that can be constructed on an individual microchip.
Recently, LeProust et al. improved the quality of microchip-synthesized oligonucleotides by 
controlling depurination during the synthesis process15. These arrays produce up to 55,000 
200mer oligonucleotides on a single chip and are sold as a ~1–10 picomole pools of 
oligonucleotides termed OLS (Oligo Library Synthesis). Several groups have used OLS 
pools for use in DNA capture technologies, promoter analysis, and DNA barcode 
development16,17,18,19,20. We have previously shown that individual oligonucleotides in a 
55,000 150mer OLS pool were evenly distributed18. We reanalyzed this data set to provide a 
rough estimate of the error rates (see Methods online) and found the error rate of this OLS 
pool was ~1/500bp both before and after PCR amplification, suggesting that the OLS pools 
can be used for accurate large-scale gene synthesis (see Supplementary Table 1 online).
We used these OLS pools to test if they would provide a better starting point for more 
scalable DNA microchip-based gene synthesis methods. We designed two OLS pools (OLS 
Pools 1 & 2) of different lengths, each containing ~13,000 130mer or 200mer 
oligonucleotides respectively. Figure 1 is a general schematic of our methods for utilizing 
OLS pools in a gene synthesis platform. Briefly, we designed oligonucleotides that were 
then printed on DNA microchips and recovered as a mixed pool of oligonucleotides (OLS 
Pool). Next, we took advantage of the long oligonucleotide lengths to independently PCR 
amplify and process only those oligonucleotides required for a given gene assembly. For the 
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200mer OLS Pool 2, we first amplified a “plate subpool” that contained DNA to construct 
up to 96 genes, and then amplified individual “assembly subpools” to separate the 
oligonucleotides for an individual gene. For the 130mer OLS Pool 1, we directly amplified 
into assembly subpools, foregoing the plate subpool step. Next, the primers used for these 
amplification steps were removed by either Type IIS restriction endonucleases to form 
double-stranded DNA (dsDNA) fragments (OLS Pool 2), or a combination of enzymatic 
steps to form single-stranded DNA (ssDNA) fragments (OLS Pool 1).
Finally, we used PCR assembly to construct full-length genes, performed enzymatic error 
correction to improve error rates if necessary, and finally cloned and characterized the 
constructs.
Obtaining subpools of only those DNA fragments required for any particular assembly is 
crucial for robust gene synthesis in very large DNA backgrounds. In addition, isolating 
subpools relieves constraints on sequence similarity inherent in past approaches. To 
facilitate this, we designed 20mer PCR primer sets with low potential cross-hybridization 
(“orthogonal” primers) derived from a set of 244,000 25mer orthogonal sequences 
developed for barcoding purposes21. Two separate orthogonal primer sets were constructed 
for the different OLS pools because of their varying requirements for downstream 
processing. Both sets were screened for potential cross-hybridization, low secondary 
structure, and matched melting temperatures to construct large sets of orthogonal PCR 
primer pairs.
To construct genes from the OLS pools, we developed automated algorithms to split the 
sequence into overlapping segments with matching melting temperatures such that they 
could be later assembled by PCR. Genes on OLS Pool 1 and 2 were designed differently to 
test the effect of different overlap lengths. We designed genes on OLS Pool 1 such that the 
processed ssDNA pools fully overlapped to form a complete dsDNA sequence. In OLS Pool 
2, the processed dsDNA fragments partially overlapped by ~20 bp and can be assembled 
into a contiguous gene sequence using PCR. We initially constructed a set of fluorescent 
proteins to test the efficacy of the gene synthesis methods on both OLS Pools.
For OLS Pool 1, we designed two independent “assembly subpools” that encoded for 
GFPmut3b plus flanking orthogonal primer sequences that are later used for PCR assembly 
(“construction primers”). The two assembly subpools, GFP43 and GFP35, differed in the 
average overlap length (43 and 35 bp, respectively), total length (82–90 and 64–78 bases, 
respectively), and number of oligonucleotides (18 and 22, respectively). We also designed 
two subpools, Control Subpools 1 and 2, containing ten and five 130mer oligonucleotides, 
respectively, to test amplification efficacy. The other eight subpools, containing a total of 
12,945 130mer sequences, were constructed on the same chip but were not used in this study 
except to provide potential sources of cross-hybridization. Each of these 12 subpools was 
flanked with independent orthogonal primer pairs (“assembly-specific primers”). As a 
control, we used these same algorithms to design a set of shorter CPG oligonucleotides (20 
bp average overlap; 35–45 bases in length; and 39 total oligonucleotides) encoding 
GFPmut3b and obtained them from a commercial provider (IDT). These oligonucleotides 
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were combined to form a third pool that was also tested (“GFP20”). All synthesized 
oligonucleotides used in the study can be found in the Supplementary Materials online.
Each of the four subpools (GFP43, GFP35, Control 1, and Control 2) were PCR amplified 
from the synthesized OLS pool using modified primers that facilitated downstream 
processing (see Supplementary Figs. 1 and 2a online)18. The oligonucleotides were then 
processed to remove primer sequences (see Supplementary Figs. 2b and 3 online). Briefly, 
lambda exonuclease was used to make the PCR products single stranded, and then uracil 
DNA glycosylase, Endonuclease VIII, and DpnII restriction endonuclease were used to 
cleave off the assembly-specific primers. The resultant gel shows that while the reaction was 
efficient, unprocessed oligonucleotide still remained. In addition, we observed spurious 
cleavage by DpnII that was likely due to the extensive overlap within the subpool that is 
inherent in the gene synthesis process. We assembled the GFP43, GFP35, and GFP20 
subpools using PCR, which resulted in GFP-sized products as well as many incorrect low 
molecular weight products (Fig. 2a).
We gel isolated, digested, and then cloned the assembly products into an expression vector 
(Fig. 2b and Supplementary Fig. 4 online). We used flow cytometry tests, manual colony 
counts, and sequencing of individual clones to measure the error rates (see Supplementary 
Figs. 5a and 5b online). All three of the assays correlated well, and the error rates 
determined through sequencing were 1/1,500 bp, 1/1,130 bp, and 1/1,350 bp for the GFP43, 
GFP35, and GFP20 synthesis reactions, respectively (See Fig. 3 and Supplementary Table 2 
online).
These results demonstrated a number of important findings. First, our subpool assembly 
primers were sufficiently well-designed to provide stringent subpool amplification of as few 
as 5 oligonucleotides out of a 12,995 oligonucleotide background. Second, the relative 
quantities of the oligonucleotides in the assembly subpools were sufficient to allow PCR 
assembly. Third, the error rates from 130mer OLS pools are sufficient to construct gene-
sized fragments (717 bp) such that >50% of the sequences will be perfect. In fact, the error 
rates from both the GFP43 and GFP35 assemblies were indistinguishable from the column-
synthesized GFP20 assemblies. Fourth, our data showed that the level of fluorescence of our 
gene assemblies correlated with the number of constructs with perfect sequence, providing a 
useful screen to test fluorescent gene assemblies in OLS Pool 2 (see Supplementary Fig. 6 
online). Finally, while PCR assembly was able to generate full-length product, many smaller 
misassembled products were also formed, requiring the use of difficult-to-automate gel 
isolation steps.
In OLS Pool 2, we designed 836 assembly subpools split into 11 plate subpools, encoding 
2,456,706 bases of oligonucleotides that could potentially result in 869,125bp of final 
assembled sequence. We first constructed three fluorescent proteins to test assembly 
protocols in OLS Pool 2: mTFP1, mCitrine, and mApple. We found that the PCR assembly 
protocols developed for ssDNA subpools in OLS Pool 1 only produced short (<200 bp) 
misassemblies when applied to the dsDNA subpools in OLS Pool 2. We tested over 1,000 
assembly PCR conditions by varying parameters such as DNA concentration, annealing 
temperatures, cycle numbers, polymerase choice, and buffer conditions. Using the best 
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protocol (see Supplementary Note 1), we assembled the three genes with no detectable 
misassemblies, thereby removing the need for gel isolation (Fig. 2c and Supplementary Figs. 
7a and 7b). Cloning followed by flow cytometry screening showed that 6.8%, 7.5%, and 
6.8% of the cells were fluorescent for mTFP1, mCitrine, and mApple assemblies, 
respectively (see Fig. 3a).
Assuming 6% correct sequence per construct and no selection against errors in the assembly 
process, the error rate was ~1/250 bp for 200mer OLS Pool 2, significantly above that of the 
estimates for 130mer OLS Pool 1 (~1/1000 bp) and the sequenced 55K 150mer OLS pool 
(~1/500 bp). This is not completely unexpected, as the amount of depurination is dependent 
upon the number of deprotection steps during synthesis and thus the oligonucleotide length. 
Despite the higher error rate, there were several advantages to the 200mer OLS Pool 2. First, 
the extensive overlaps designed in OLS Pool 1 caused spurious processing of the primers 
from the assembly subpools. The use of Type IIs restriction endonucleases to process 
primers to form dsDNA resulted in more robust processing. Second, the use of two 
amplification steps conserves chip-eluted DNA to allow for future scaling of the gene 
synthesis process (See Supplementary Note 2). Third, the assemblies of OLS Pool 1 
produced many smaller bands and required lower-throughput gel isolation procedures. This 
could be due to mispriming during PCR assembly because of the long overlap lengths used 
in the design process. The assemblies in OLS Pool 2 used much shorter overlap lengths, and 
resulted in no smaller molecular weight misassembled products.
In order to improve the error rates of the genes assembled from OLS Pool 2, we used 
ErrASE, a new commercially-available enzyme cocktail, to remove errors in the assembled 
fluorescent proteins. For each gene, we applied ErrASE at six different stringencies, re-
amplified the constructs, cloned the PCR products, and re-screened the cloned genes using 
flow cytometry. Improvement of the level of fluorescence progressively increased with 
increased ErrASE stringency. At the highest levels of error correction, the fluorescence 
levels were 31%, 49%, and 26% for mTFP1, mCitrine, and mApple respectively (see Fig. 3a 
and Supplementary Fig. 8 online). We also performed the ErrASE procedure on our GFP43 
and GFP35 pools from OLS Pool 1, resulting in fluorescence levels of 89% and 92% 
respectively (Fig. 3a and Supplementary Fig. 5c). We sequenced clones of GFP43 and 
GFP35 and found 3 errors in 21,510 (1/7170 bp) and 4 errors in 20,076 (1/5019 bp) 
sequenced bases, respectively.
As a more challenging test for our DNA synthesis technology, we designed and synthesized 
oligonucleotides for 42 genes encoding single-chain Fv (scFv) regions corresponding to a 
number of well-known antibodies in OLS Pool 2. We have previously had trouble 
synthesizing these genes using commercial gene synthesis companies. This might be partly 
due to the prototype (Gly4Ser)3 linker, which is designed to maximize flexibility and allow 
the heavy and light V regions to assemble22. The repetitive nature and high GC content of 
the linker-encoding sequences often represents a challenge for accurate DNA synthesis. We 
therefore tested three different linker sequences that varied in GC content and repetitive 
character of the linker encoding sequence. In addition, the presence of high sequence 
homology in the antibody backbones and linkers represented a potential source of cross-
hybridization that could interfere with assembly.
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As expected, the antibody sequences did not assemble as robustly as the fluorescent proteins 
and thus we further optimized the conditions during pre-and post-assembly (see 
Supplementary Figs. 7c, 9, and 10a online). Under the best protocol, 40of the 42 constructs 
assembled to the correct size (see Fig. 2d and Supplementary Table 3 online). The two 
misassembled genes displayed faint bands at the correct size, which were gel isolated and 
reamplified to produce strong bands of the correct size. We sequenced 15 antibodies 
including representatives from all three linker types. We performed enzymatic error 
correction using ErrASE, gel isolated the product and finally cloned the constructs into an 
expression vector. One of the 15 antibodies did not clone, and another had a deleted linker 
region in all 21 sequenced clones. Both of these antibodies were encoded with the highest 
GC content linker. The average error rate of the 14 antibodies that did clone was1/315 bp 
(see Fig. 3b and Supplementary Table 2 online); this was significantly higher than the GFP 
assemblies, but still sufficient for construction of genes of this size (~10% clones should be 
perfect on average). In addition, sequence analysis showed no instances of subpool cross-
contamination during the assembly process.
Our results show for the first time the assembly of gene-sized DNA fragments totaling 
~35,000 bp from oligonucleotide pools of more than >50 kilobases. A number of key 
features are important to make the process work including the use of low-error starting 
material, well-chosen orthogonal primers, subpool amplification of individual assemblies, 
optimized assembly methods, and enzymatic error correction. We describe two separate 
OLS pool lengths and assembly methods, which have their own advantages and 
disadvantages (see Supplementary Fig. 1 online). The shorter, 130mer OLS Pool 1 
assemblies have lower error rates, but because there are no plate amplifications, will be 
harder to scale as we begin to utilize larger OLS pools. The longer 200mer OLS Pool 2 is 
easier to scale, but contained higher error rates. The costs of oligonucleotides in both 
processes are less than $0.01/bp of final synthesized sequence, and thus the dominant costs 
are enzymatic processing, cloning, and sequence verification. Future work on lowering cost 
of perfect sequence will focus on the ability to lower sequencing costs such as by using 
cheaper next-generation sequencing technologies, or by incorporating other error-correction 
techniques such as PAGE selection of oligonucleotide pools or mutS-based error 
filtration3,23.
Online Methods
Reanalysis of OLS Pool Error Rates
We reanalyzed a previously published data set for determining sequencing error rates24. 
Briefly, the dataset was derived from high-throughput sequencing using the Illumina 
Genome Analyzer platform of a 53,777 150mer OLS pool. Two sequencing runs were 
performed; the first before any amplification, and the second after two rounds of ten cycles 
of PCR (20 cycles total). As our previous analyses were mostly looking for distribution 
effects, we reanalyzed this existing data to get an estimate of error rates pre-and post-PCR 
amplification. We realigned the dataset using Exonerate to allow for gapped alignments and 
analysis of indels25. Specifically, we used an affine local alignment model that is equivalent 
to the classic Smith-Waterman-Gotoh alignment, a gap extension penalty of -5, and used the 
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full refine option to allow for dynamic programming based optimization of the alignment. 
These reads were solely mapped on base calls by the Illumina platform. We used these 
alignments to count mismatches, deletions, and insertions as compared to the designed 
sequences. However, since base-calling can be more error prone on next generation 
platforms than traditional Sanger-based approaches, we filtered the results based only on 
high-quality base-calls (Phred scores of 30 or above or >99.9% accuracy). This was 
accomplished by converting Illumina quality scores to Phred values using the Maq utility 
sol2sanger25 and only using statistics from base calls of Phred 30 or higher. All error rate 
analysis scripts were implemented in Python and are available upon request. While this 
method provides an estimate for error rates, unmapped reads may have higher error rates and 
thus underestimating the total average error rate. In addition, base-calling errors might still 
overestimate the error rate. Finally, using only high-quality base calls, which usually occur 
only in the first 10 bases of a read, might only reflect error rates on the 5′ end of the 
synthesized oligonucleotide.
Design and Synthesis of OLS Pools
The 13,000 oligos in the first OLS library (“OLS Pool 1”) were broken up into 12 separately 
amplifiable subpools (“assembly subpools). Each assembly subpool was defined by unique 
20 bp priming sites that flanked each of the oligos in the pool. The priming sites were 
designed to minimize amplification of oligos not in the particular assembly subpool. This 
was done by designing set of orthogonal 20-mers (“assembly-specific primers”) using a set 
of 240,000 orthogonal 25-mers designed by Xu et al.21 as a seed. From these sequences we 
selected 20-mers with 3′ sequence ending in thymidine or ‘GATC’ for the forward and 
reverse primers respectively. We screened for melting temperatures between 62–64 °C and 
low primer secondary structure. After the additional filtering, 12 pairs of forward and 
reverse primers were chosen to be the assembly-specific primers. The 13,000 oligos in the 
second OLS library (“OLS Pool 2”) were broken up into 11 subpools corresponding to 11 
sets of up to 96 assemblies (“plate subpools”), which were further divided into a total of 836 
assembly subpools. A new set of orthogonal primers were designed similarly to the previous 
set (without the GATC and thymidine constraints) but further filtered to remove Type IIS 
restriction sites, secondary structure, primer dimers, and self-dimers. The final set of primer 
pairs was distributed among the plate-specific primers, assembly-specific primers, and 
construction primers. See Supplementary Methods online for more detailed design 
information and primer sequences.
OLS pools were synthesized by Agilent Technologies, and are available upon signing a 
Collaborative Technology Development agreement with Agilent. Costsof OLS pools area 
function of the number of unique oligos synthesized and of the length of the oligos (<$0.01 
per final assembled base-pair for all scales used in this study). OLS Pools 1 and 2 were 
independently synthesized, cleaved, and delivered as lyophilized ~1–10 picomole pools.
Amplification and processing of OLS subpools
Lyophilized DNA from OLS Pools 1 and 2 were resuspended in 500 μL TE. Assembly 
subpools were amplified from 1 μL of OLS Pool 1 in a 50 μL qPCR reaction using the 
KAPA SYBR FAST qPCR kit (Kapa Biosystems). A secondary 20 mL PCR amplification 
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using Taq polymerase was performed from the primary amplification product. The barcode 
primer sites were removed using a technique previously described20. In brief, the forward 
primers contained a phosphorothioate bond at the 5′ end and the last nucleotide on the 3′ end 
was a deoxyuridine; the reverse primers contained a DpnII recognition site (‘GATC’) at the 
3′ end and a phosphorylated 5′ end. PCR amplification was followed by γ exonuclease 
digestion of 5′ phosphorylated strands, hybridization of the 3′ primer site to its complement, 
and cleavage of the 5′ and 3′ primer sites using USER enzyme mix and DpnII (New England 
Biolabs), respectively. Plate subpools were amplified from1 μL of OLS Pool 2 in 50 μL 
Phusion polymerase PCR reactions. Assembly subpools were amplified from the plate 
subpools by 100μL Phusion polymerase PCR reactions. A BtsI digest removed the forward 
and reverse primer sites. See the Supplementary Methods online for more detailed protocols.
Assembly of fluorescent proteins
GFPmut326 was assembled from the OLS Pool 1 assembly subpools by PCR. The GFP43 
and GFP35 subpools were designed such there was full overlap between neighboring oligos 
during assembly, with average overlaps of 43 bp and 35 bp for GFP43 and GFP35, 
respectively. For the first set of assemblies, 330 pg of the GF43 subpool or 40 pg of the 
GFP35 subpool were used per 20 μL Phusion polymerase PCR assembly. The full-length 
product was gel-isolated, amplified using Phusion polymerase, and cloned into pZE21 after 
a HindIII/KpnI digest. The second set of assemblies was built using a similar procedure, 
except that the assembly PCR used 170 pg or 190 pg of GFP43 and GFP35 subpools, 
respectively; and the gel-isolated product was not re-amplified prior to cloning.
Oligonucleotides for mTFP1, mCitrine, and mApple were designed such that there was on 
average a 20 bp overlap between adjacent oligonucleotides. The proteins were built from 
OLS Pool 2 assembly subpools by first performing a KOD polymerase pre-assembly 
reaction that was done in the absence of construction primers followed by a KOD 
polymerase assembly PCR in which the construction primers were included. ErrASE error 
correction was then performed on aliquots of the synthesis products following the 
manufacturer’s instructions. The assembled product was digested with HindIII and KpnI and 
cloned into pZE21. Sequencing of clones was performed by Beckman Coulter Genomics. 
See the Supplementary Methods online for more detailed protocols.
ErrASE
ErrASE is an enzyme cocktail designed to remove errors in synthetically assembled genes 
(Novici Biotech, Vacaville CA). Assembled genes are denatured and re-annealed to allow 
for the formation of hetero-duplexes. A resolvase enzyme in ErrASE then recognizes and 
cuts at mismatched positions. Other enzymes in the cocktail remove these cut mismatched 
positions. The products could then be reamplified by PCR to reassemble the full-length 
gene.
Specifically, sixaliquots of 10–50 ng of each assembled gene was added to 10 μL of PCR 
buffer (we have also tested the effects of including betaine in the buffer see Supplementary 
Fig. 11). Hetero-duplexes were formed by denaturing at 95°C and slowly cooling to room 
temperature. Each aliquot was then used to resuspend six different lyophilized ErrASE 
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mixtures of increasing stringency provided by the manufacturer. After a 1–2 hour room 
temperature incubation, the assemblies were re-amplified and visualized on an agarose gel. 
Of the reactions that resulted in a correctly-sized band, the one that used the most stringent 
ErrASE protocol was selected for cloning.
Flow cytometry
Fluorescent cell fractions of the cloned libraries of assembly products were quantified using 
a BD LSR Fortessa flow cytometer either a 488 nm laser with a 530 nm filter (30 nm 
bandpass) or a 561 nm laser with a 610 nm filter (20 nm bandpass).
Synthesis of Antibodies
125 ng of each antibody assembly pool was pre-assembled in 20 μL KOD pre-assembly 
reactions. We then tested 9 amplification protocols for the ability to amplify the 42 antibody 
pre-assemblies into full-length genes. We attempted to clone 8 constructs from the best 
assembly protocol (afutuzumab, efungumab, ibalizumab, oportuzumab, panobacumab, 
robatumumab, ustekinumab, and vedolizumab; see Supplementary Fig. 10a and 
Supplementary Table 3). The 8 assemblies were error-corrected using ErrASE, gel-isolated, 
re-amplified using Phusion polymerase, gel-isolated again, and cloned into pSecTag2A after 
an ApaI/SfiI digest. Sequencing was performed by Genewiz. All but oportuzumab cloned 
successfully. We then repeated the experiment, increasing the amount of assembly pool 
DNA in the pre-assembly reaction to 400 ng. We selected a different set of 8 constructs from 
this second set of assemblies for cloning (abagovomab, alemtuzumab, ranibizumab, 
cetuximab, efungumab, pertuzumab, tadocizumab, and trastuzumab; see Fig. 2d and 
Supplementary Table 3). Using the same methods as with the first set of cloned antibodies, 
this second set was error-corrected, gel-isolated, cloned, and sequenced. See the 
Supplementary Methods online for more detailed protocols.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Scalable gene synthesis platform schematic for OLS Pool 2
Pre-designed oligonucleotides (no distinction is made between dsDNA and ssDNA in the 
figure) are synthesized on a DNA microchip (a) and then cleaved to make a pool of 
oligonucleotides (b). Plate-specific primer sequences (yellow or brown) are used to amplify 
separate Plate Subpools (c) (only two are shown), which contain DNA to assemble different 
genes (only three are shown for each plate subpool). Assembly specific sequences (shades of 
blue) are used to amplify assembly subpools (d) that contain only the DNA required to make 
a single gene. The primer sequences are cleaved (e) using either Type IIS restriction 
enzymes (resulting in dsDNA) or by DpnII/USER/γ exonuclease processing (producing 
ssDNA). Construction primers (shown as white and black sites flanking the full assembly) 
are then used in an assembly PCR reaction to build a gene from each assembly subpool (f). 
Depending on the downstream application the assembled products are then cloned either 
before or after an enzymatic error correction step.
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Figure 2. Gene synthesis products
GFPmut3 was PCR assembled (a) from two different assembly subpools (GFP42 and 
GFP35) that were amplified from OLS Pool 1. Because the majority of the products were of 
the wrong size, we gel-purified the full-length assemblies and re-amplified them (b). Using 
the longer oligonucleotides in OLS Pool 2 we were able to develop a PCR assembly 
protocol that did not require gel-isolation, which we used to build three different fluorescent 
proteins (c). We then attempted to build 42 scFv regions that contained challenging GC-rich 
linkers. Of the 42 assemblies (d) 40 resulted in strong bands of the correct size. We gel 
isolated and re-amplified the two that did not assemble (7 and 24) resulting in bands of the 
correct size (see Supplementary Fig. 10b online). The antibody that corresponds to each 
number is given in Supplementary Table 3 online.
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Figure 3. Characterization of products from OLS Pools 1 and 2
The percentage of fluorescent cells resulting from synthesis products derived from column-
synthesized oligonucleotides (black), OLS Chip 1 subpools GFP43 and GFP35 (green) and 
the three fluorescent proteins produced on OLS Chip 2 with and without ErrASE treatment 
(blue, yellow, and orange) are shown (a). The error bars correspond to the range of 
replicates from separate ligations. The error rates (average bp of correct sequence per error) 
from various synthesis products are shown (b). Error bars show the expected Poisson error 
based on the number of errors found (±√n). Deletions of more than 2 consecutive bases are 
counted as a single error (no such errors were found in OLS Pool 1).
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